TScan Therapeutics, Inc. (TCRX)
$2.71
Rating:
Recommendation:
-
| Symbol | TCRX |
|---|---|
| Price | $2.71 |
| Beta | 0.333 |
| Volume Avg. | 0.13M |
| Market Cap | 129.589M |
| Shares () | - |
| 52 Week Range | 1.45-6.03 |
| 1y Target Est | - |
| DCF Unlevered | TCRX DCF -> | |
|---|---|---|
| DCF Levered | TCRX LDCF -> | |
| ROE | -67.75% | Strong Sell |
| ROA | -25.90% | Sell |
| Operating Margin | - | |
| Debt / Equity | 46.03% | Neutral |
| P/E | -1.05 | Sell |
| P/B | 0.67 | Buy |
Latest TCRX news
About
Download (Excel)TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.